Innovative FGF1 protein analogues in the treatment of type 2 diabetes

Fibroblast growth factor 1 (FGF1) is an autocrine and paracrine regulator which plays an important role in the proliferation processes. Latest reports confirm its effect on glucose homoeostasis, and therefore creation of an analogue of this protein seems to be an attractive therapeutic objective. Celon Pharma is conducting research aiming at developing an innovative FGF1 analogue which could become a breakthrough therapy in type 2 diabetes.